How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,081 results for

Sublingual Immunotherapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Utility of component analyses in subjects undergoing sublingual immunotherapy for peanut allergy. (PubMed)

Utility of component analyses in subjects undergoing sublingual immunotherapy for peanut allergy. Sublingual immunotherapy (SLIT) with peanut changes clinical and immune responses in most peanut-allergic individuals, but the response is highly variable.We sought to examine the component-specific effects of peanut SLIT and determine whether peanut component testing could predict the outcome of a double-blind, placebo-controlled food challenge (DBPCFC) after 12 months of peanut SLIT.We included

Full Text available with Trip Pro

2015 Clinical and Experimental Allergy

162. Sublingual Allergen Immunotherapy in HIV positive patients. (PubMed)

Sublingual Allergen Immunotherapy in HIV positive patients. HIV infection is a relative contraindication for allergic immunotherapy (AIT). In the last decade, highly active antiretroviral therapy (HAART) has improved the immune function and life expectancy in HIV-infected patients whose respiratory allergic incidence is similar to the general population. We evaluated the safety and clinical effectiveness of sublingual immunotherapy in a group of grass pollen-allergic HAART-treated HIV-positive (...) patients. Thirteen patients received sublingual immunotherapy (SLIT) tablet (Oralair, Stallergenes©) and symptomatic therapy and were compared with nine patients receiving symptomatic therapy alone. Clinical benefits were evaluated by the analysis of total combined score (TCS), sum of symptom-medication score, and a quality of life (QoL) questionnaire. HIV viral load and peripheral TCD4 lymphocytes were analyzed at the beginning and at the end of the study. Clinical efficacy data showed a significant

2015 Allergy

163. House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: a clinical trial. (PubMed)

House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: a clinical trial. The safety of allergen immunotherapy (AIT) in asthma has not always been sufficiently documented; accordingly, fear of asthma exacerbations has made physicians somewhat reluctant to prescribe AIT in this context. In a double-blind, placebo-controlled, randomized clinical trial, house dust mite (HDM) sublingual AIT was found to be efficacious in moderate, persistent asthma (...) . The trial's safety results are now reported in detail.Asthmatic adults were randomized 2 : 1 to twelve months of daily treatment with a sublingual solution of Dermatophagoides pteronyssinus and Dermatophagoides farinae extracts or a placebo. Adverse events (AEs) at least possibly related to the investigational product were classified by the investigators as adverse drug reactions (ADRs).Overall, the patients in the safety analysis set (n = 484; active treatment: n = 322; placebo: n = 162) had mostly well

2015 Allergy

164. Distinct modulation of allergic T cell responses by subcutaneous versus sublingual allergen-specific immunotherapy. (PubMed)

Distinct modulation of allergic T cell responses by subcutaneous versus sublingual allergen-specific immunotherapy. Allergen-specific immunotherapy is the only curative treatment for type I allergy. It can be administered subcutaneously (SCIT) or sublingually (SLIT). The clinical efficacy of these two treatment modalities appears to be similar, but potential differences in the immunological mechanisms involved have not been fully explored.To compare changes in the allergen-specific T cell (...) response induced by subcutaneous vs. sublingual administration of allergen-specific immunotherapy (AIT).Grass pollen-allergic patients were randomized into groups receiving either SCIT injections or SLIT tablets or neither. PBMCs were tested for Timothy grass (TG)-specific cytokine production by ELISPOT after in vitro expansion with TG-peptide pools. Phenotypic characterization of cytokine-producing cells was performed by FACS.In the SCIT group, decreased IL-5 production was observed starting 10 months

Full Text available with Trip Pro

2015 Clinical and Experimental Allergy

165. Timothy specific IgE levels are associated with efficacy and safety of timothy grass sublingual immunotherapy tablet. (PubMed)

Timothy specific IgE levels are associated with efficacy and safety of timothy grass sublingual immunotherapy tablet. Regional pollen allergen exposure differences may induce variable sensitization profiles that could affect allergen immunotherapy efficacy and safety.To describe sensitization profiles against timothy grass allergen components (Phl p) in North American subjects screened for a timothy grass sublingual immunotherapy (SLIT) tablet trial and evaluate grass SLIT tablet efficacy

2015 Asthma & Immunology

166. Changes of micro-RNAs in asymptomatic subjects sensitized to Japanese cedar pollen after prophylactic sublingual immunotherapy. (PubMed)

Changes of micro-RNAs in asymptomatic subjects sensitized to Japanese cedar pollen after prophylactic sublingual immunotherapy. Japanese cedar pollinosis is the predominant seasonal allergic rhinitis in Japan, and it has increased in prevalence during the past 10 years. Sublingual immunotherapy (SLIT) is considered a safe and effective treatment for pollinosis. Micro-RNAs (miRNAs) are a class of short single-stranded RNA molecules that posttranscriptionally silence gene expression and may

Full Text available with Trip Pro

2015 Allergy & rhinology (Providence, R.I.)

167. Effect of high-dose sublingual immunotherapy on respiratory infections in children allergic to house dust mite. (PubMed)

Effect of high-dose sublingual immunotherapy on respiratory infections in children allergic to house dust mite. Allergic rhinitis is characterized by eosinophil inflammation. Allergic inflammation may induce susceptibility to respiratory infections (RI). House dust mite (HDM) sensitization is very frequent in childhood. Allergen immunotherapy may cure allergy as it restores a physiologic immune and clinical tolerance to allergen and exerts anti-inflammatory activity.This study investigated (...) whether six-month high-dose, such as 300 IR (index of reactivity), HDM-sublingual immunotherapy (SLIT) could affect RI in allergic children.Globally, 40 HDM allergic children (18 males; mean age, 9.3 years) were subdivided in 2 groups: 20 treated by symptomatic drugs (group 1) and 20 by high-dose HDM-SLIT (group 2), since September 2012 to April 2013. The daily maintenance dose of HDM-SLIT was 4 pressures corresponding to 24, 4.8, and 60 µg, respectively of the major allergens Dermatophagoides

Full Text available with Trip Pro

2015 Asia Pacific allergy

168. The efficacy and safety of the Timothy grass allergy sublingual immunotherapy tablet in Canadian adults and children. (PubMed)

The efficacy and safety of the Timothy grass allergy sublingual immunotherapy tablet in Canadian adults and children. The effect of sublingual Timothy grass immunotherapy tablet 2800 BAU (grass SLIT-T) has been evaluated in three North American trials in adults and children who have allergic rhinitis with or without conjunctivitis (AR/C). This paper examines the effects of grass SLIT-T in Canadians.Data for grass-allergic Canadians in three randomized, placebo-controlled, double-blind trials

Full Text available with Trip Pro

2015 Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology

169. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, open, parallel-group study. (PubMed)

Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, open, parallel-group study. 25304342 2015 01 29 2014 12 03 1534-4436 113 6 2014 Dec Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology Ann. Allergy Asthma Immunol. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, open, parallel-group study. 671-673.e1 10.1016/j.anai.2014.09.009 S1081-1206(14)00650 (...) therapy immunology Child Child, Preschool Conjunctivitis, Allergic complications diagnosis drug therapy immunology Dermatitis, Atopic complications diagnosis drug therapy immunology Dermatophagoides pteronyssinus immunology Drug Administration Schedule Female Humans Male Rhinitis, Allergic complications diagnosis drug therapy immunology Skin drug effects immunology pathology Sublingual Immunotherapy Vaccines administration & dosage therapeutic use 2014 04 26 2014 09 04 2014 09 05 2014 10 12 6 0 2014

2015 Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

170. Choosing the optimal dose in sublingual immunotherapy: Rationale for the 300 index of reactivity dose (PubMed)

Choosing the optimal dose in sublingual immunotherapy: Rationale for the 300 index of reactivity dose Sublingual immunotherapy (SLIT) is an effective and well-tolerated method of treating allergic respiratory diseases associated with seasonal and perennial allergens. In contrast to the subcutaneous route, SLIT requires a much greater amount of antigen to achieve a clinical effect. Many studies have shown that SLIT involves a dose-response relationship, and therefore it is important to use

Full Text available with Trip Pro

2015 Clinical and translational allergy

171. The effects of house dust mite sublingual immunotherapy in patients with allergic rhinitis according to duration. (PubMed)

The effects of house dust mite sublingual immunotherapy in patients with allergic rhinitis according to duration. The safety and efficacy of sublingual immunotherapy (SLIT) have been demonstrated in the recent 2 decades. However, the data is still mixed regarding the efficacy of house dust mite (HDM) SLIT. The objective of this work was to evaluate the different clinical efficacy SLIT in patients with allergic rhinitis (AR) according to different durations of treatment.A total of 500 subjects

2015 International forum of allergy & rhinology

172. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites. (PubMed)

Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites. Sublingual immunotherapy (SLIT) tablets could be an important alternative to subcutaneous immunotherapy for house dust mite (HDM) allergy in children.To characterize the safety, tolerability, and duration of local adverse events (AEs) of an HDM SLIT tablet (MK-8237; Merck, ALK Abellò, and Torii) in North American children 12 to 17 years old with HDM allergic rhinitis

2015 Asthma & Immunology

173. Efficacy of Sublingual Immunotherapy with Dermatophagoides farinae Extract in Monosensitized and Polysensitized Patients with Allergic Rhinitis: Clinical Observation and Analysis (PubMed)

Efficacy of Sublingual Immunotherapy with Dermatophagoides farinae Extract in Monosensitized and Polysensitized Patients with Allergic Rhinitis: Clinical Observation and Analysis To investigate differences in the efficacy of sublingual immunotherapy with Dermatophagoides farinae drops in monosensitized and polysensitized allergic rhinitis patients.The patients enrolled in the study were treated for more than one year by sublingual immunotherapy (SLIT) using Dermatophagoides farinae drops (...) and polysensitized patients could be cured by SLIT using Dermatophagoides farinae drops. This study provides a reference for the selection of allergens to be used in immunotherapy for polysensitized AR patients.

Full Text available with Trip Pro

2015 BioMed research international

174. Efficacy of Grass Pollen Allergen Sublingual Immunotherapy Tablets for Seasonal Allergic Rhinoconjunctivitis: A Systematic Review and Meta-analysis. (PubMed)

Efficacy of Grass Pollen Allergen Sublingual Immunotherapy Tablets for Seasonal Allergic Rhinoconjunctivitis: A Systematic Review and Meta-analysis. Randomized clinical trials (RCTs) and meta-analyses of sublingual immunotherapy (SLIT) for the treatment of seasonal allergic rhinoconjunctivitis (SARC) have shown a modest clinical benefit compared with placebo. Furthermore, indirect comparison by meta-analyses showed that subcutaneous immunotherapy is more effective than SLIT. Despite these data (...) , SLIT has become the most prescribed treatment of SARC in Europe in recent years, and it was approved by the US Food and Drug Administration for the treatment of SARC to grass pollen in the United States on April 1, 2014.To assess the efficacy and safety of the grass pollen sublingual tablets licensed as drugs in the treatment of patients with SARC to grass pollen.Computerized bibliographic searches of MEDLINE, EMBASE, the Cochrane Library, and ClinicalTrials.gov (from inception to April 30, 2014

Full Text available with Trip Pro

2015 JAMA Internal Medicine

175. Sublingual Immunotherapy for Allergic Fungal Sinusitis. (PubMed)

Sublingual Immunotherapy for Allergic Fungal Sinusitis. Allergic fungal sinusitis (AFS) is a condition that has an allergic basis caused by exposure to fungi in the sinonasal tract leading to chronic inflammation. Despite standard treatment modalities, which typically include surgery and medical management of allergies, patients still have a high rate of recurrence. Subcutaneous immunotherapy (SCIT) has been used as adjuvant treatment for AFS. Evidence exists to support the use of sublingual (...) immunotherapy (SLIT) as a safe and efficacious method of treating allergies, but no studies have assessed the utility of SLIT in the management of allergic fungal sinusitis. A record review of cases of AFS that are currently or previously treated with sublingual immunotherapy from 2007 to 2011 was performed. Parameters of interest included serum IgE levels, changes in symptoms, Lund-McKay scores, decreased sensitization to fungal allergens associated with AFS, and serum IgE levels. Ten patients

2015 Rhinology and Laryngology

176. Efficacy and Safety of Sublingual Immunotherapy for Two Seasons in Patients with Japanese Cedar Pollinosis. (PubMed)

Efficacy and Safety of Sublingual Immunotherapy for Two Seasons in Patients with Japanese Cedar Pollinosis. Japanese cedar (JC) pollinosis is the most common seasonal allergic rhinitis in Japan. Standardized JC pollen extract is available for subcutaneous immunotherapy, but this treatment is limited by potentially serious side effects. The aim of this double-blind, randomized comparative study was to evaluate the efficacy and safety of standardized JC pollen extract in a new oral formulation (...) (CEDARTOLEN®, Torii Pharmaceutical Co., Ltd., Tokyo, Japan) for sublingual immunotherapy (SLIT) for JC pollinosis.A total of 531 subjects with JC pollinosis were randomized into 2 groups at a ratio of 1:1 to receive daily sublingual administration of standardized JC pollen extract with a maintenance dose of 2,000 Japanese allergy units (JAU) or placebo for 2 consecutive pollen seasons. The efficacy was evaluated using the total nasal symptom and medication score (TNSMS) as the primary end point. Secondary

Full Text available with Trip Pro

2015 International Archives of Allergy and Immunology

177. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. (PubMed)

SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. House dust mite (HDM) allergy is associated with persistent allergic rhinitis (AR) and allergic asthma.To investigate the efficacy and safety of a SQ HDM sublingually administered immunotherapy tablet (ALK, Hørsholm, Denmark) in adults and adolescents with HDM respiratory allergic disease and report the AR results.Six hundred

Full Text available with Trip Pro

2015 Asthma & Immunology

178. Characterization of oral immune cells in birch pollen-allergic patients: impact of the Oral Allergy Syndrome and sublingual allergen immunotherapy on antigen presenting cells. (PubMed)

Characterization of oral immune cells in birch pollen-allergic patients: impact of the Oral Allergy Syndrome and sublingual allergen immunotherapy on antigen presenting cells. A detailed characterization of human oral immune cells is needed to better understand local mechanisms associated with allergen capture following oral exposure.Oral immune cells were characterized by immunohistology and immunofluorescence in biopsies obtained from three healthy individuals and 23 birch pollen-allergic (...) patients with/without oral allergy syndrome (OAS), at baseline and after 5 months of sublingual allergen immunotherapy (AIT).Similar cell subsets (i.e., dendritic cells, mast cells, and T lymphocytes) were detected in oral tissues from healthy and birch pollen-allergic individuals. CD207+ Langerhans cells (LCs) and CD11c+ myeloid dendritic cells (DCs) were found in both the epithelium and the papillary layer of the Lamina propria (LP), whereas CD68+ macrophages, CD117+ mast cells, and CD4+ /CD8+ T

2015 Allergy

179. Clinical and cytokine responses to house dust mite sublingual immunotherapy. (PubMed)

Clinical and cytokine responses to house dust mite sublingual immunotherapy. Cytokine responses accompanying sublingual immunotherapy (SLIT) responder phenotypes have not previously been reported.To investigate clinical and cytokine responses of house dust mite (HDM) sensitive patients with allergic rhinitis receiving HDM SLIT or placebo for 2 years.Sixty adults were randomized to receive SLIT or placebo. Clinical symptoms were measured using the Total 5 Symptom Score (TSS5) and Juniper

2015 Asthma & Immunology

180. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis

The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis Compalati E, Passalacqua G, Bonini M, Canonica GW CRD summary The authors concluded that this review provided encouraging evidence which suggested (...) that sublingual immunotherapy using house dust mite extract might be efficacious in treating patients with allergic rhinitis and asthma, but that further research is required. These findings should be interpreted with caution given the potential for missing data and the likely poor reliability of the pooled data. Authors' objectives To assess the efficacy of sublingual immunotherapy using house dust mite extracts in patients with allergic rhinitis and asthma Searching MEDLINE, EMBASE, LILACS and SCOPUS were

Full Text available with Trip Pro

2009 DARE.

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>